Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Evangelos Terpos, MD PhD, Despina Fotiou, MD, Konstantinos Anargyrou, MD, Theodoros P. Vassilakopoulos, MD PhD, Dimitrios Christoulas, MD, Polyzois Makras, MD PhD, Maria Dimou, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Stavroula Masouridou, MD, Maria K. Angelopoulou, MD, Athanasios Papatheodorou, PhD, Konstantinos Tsionos, MD, Panayiotis Panayiotidis, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4124.

https://doi.org/10.1182/blood-2019-123615

Published: 2019

Journal Articles

Determination of the Percentage of CML Patients that Achieve Continuous Complete Molecular Response Under Treatment with TKIs and Are Eligible for Participation in a TKI Discontinuation Study

Blood (2011) 118 (21): 4446.

https://doi.org/10.1182/blood.V118.21.4446.4446

Published: 2011

Journal Articles

Low Bone Mineral Density and High Bone Turnover In Patients with Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study

Konstantinos Anargyrou, Theodoros P. Vassilakopoulos, Konstantinos Tsionos, Panayiotis Kokkoris, Georgios Boutsikas, Maria K. Angelopoulou, Dimitrios Christoulas, Stavroula Masouridou, Maria Dimou, Athanasios Papatheodorou, Danos N. Chatzifotiadis, Panayiotis Panayiotidis, Gerasimos A. Pangalis, Photis Beris, Evangelos Terpos

Blood (2010) 116 (21): 5071.

https://doi.org/10.1182/blood.V116.21.5071.5071

Published: 2010

Journal Articles

First-Line Chemotherapy Leads to High Bone Turnover and Reduced Bone Mass in Patients with Non-Hodgkin's Lymphoma (NHL).

Blood (2009) 114 (22): 1951.

https://doi.org/10.1182/blood.V114.22.1951.1951

Published: 2009

Journal Articles

The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.

Evangelos Terpos, Sosana Delimpasi, Konstantinos Anargyrou, Ioannis Baltathakis, Efstathios Kastritis, Anna Christoforidou, Konstantinos Tsionos, Konstantinos Tsatalas, Emmanuel Nikiforakis, Meletios A. Dimopoulos, Nikolaos Harhalakis

Blood (2007) 110 (11): 3596.

https://doi.org/10.1182/blood.V110.11.3596.3596

Published: 2007

Journal Articles

The Ratio of Angiopoietin-1 to Angiopoietin-2 Is Reduced and Predicts Independently for Survival in Newly Diagnosed Patients with Multiple Myeloma.

Meletios A. Dimopoulos, Konstantinos Anargyrou, Eirini Katodritou, Efstathios Kastritis, Anastasia Pouli, Evridiki Michali, Evgenia Verrou, Anastasia Banti, Konstantinos Tsionos, Aikaterini Stefanoudaki, Konstantinos Zervas, Evangelos Terpos

Blood (2007) 110 (11): 1478.

https://doi.org/10.1182/blood.V110.11.1478.1478

Published: 2007

Journal Articles

Cystatin-C Is a Sensitive Marker of Renal Impairment with an Independent Predictive Value for Survival in Multiple Myeloma; Reduction Post Bortezomib Monotherapy.

Evangelos Terpos, Eirini Katodritou, Evangelos Tsiftsakis, Efstathios Kastritis, Anastasia Pouli, Dimitrios Christoulas, Evridiki Michali, Evgenia Verrou, Anastasia Banti, Konstantinos Tsionos, Meletios A. Dimopoulos, Konstantinos Zervas

Blood (2007) 110 (11): 1484.

https://doi.org/10.1182/blood.V110.11.1484.1484

Published: 2007

Journal Articles

Bone Remodeling in Patients with Relapsed/Refractory Multiple Myeloma Who Receive Lenalidomide-Based Regimens.

Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, Eirini Katodritou, Xenophon Papanikolaou, Maria Roussou, Nikolaos Stavropoulos, Konstantinos Tsionos, Gerassimos A. Pangalis, Konstantinos Zervas, Orhan Sezer, Meletios A. Dimopoulos

Blood (2007) 110 (11): 4745.

https://doi.org/10.1182/blood.V110.11.4745.4745

Published: 2007

Journal Articles

Dysfunction of Toll-Like Receptor-2, −4, and −6: Is There a Role in the Pathogenesis of Immunodeficiency in Multiple Myeloma?.

Evangelos Terpos, Meletios A. Dimopoulos, Charoula Xirakia, Dimitrios Christoulas, Athanasios Anagnostopoulos, Eirini Katodritou, Kostas Zervas, Paschalis Sideras, Konstantinos Tsionos, Evangelos Andreakos

Blood (2006) 108 (11): 3430.

https://doi.org/10.1182/blood.V108.11.3430.3430

Published: 2006

Journal Articles

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1α and Angiogenic Cytokines.

Evangelos Terpos, Athanasios Anagnostopoulos, Deborah Heath, Efstathios Kastritis, Dimitrios Christoulas, Nikolaos Anagnostopoulos, Maria Roussou, Konstantinos Tsionos, Peter Croucher, Meletios A. Dimopoulos

Blood (2006) 108 (11): 3541.

https://doi.org/10.1182/blood.V108.11.3541.3541

Published: 2006

Journal Articles

Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenastrom’s Macroglobulinemia (WM): Correlations with Clinical Data.

Athanasios Anagnostopoulos, MD, Evangelos Terpos, M.D., Konstantinos Zervas, M.D., Efstathios Kastritis, M.D., Vangelis Eleftherakis-Papaiakovou, M.D., Irini Katodritou, M.D., Konstantinos Tsionos, M.D., Meletios A. Dimopoulos, M.D.

Blood (2006) 108 (11): 5006.

https://doi.org/10.1182/blood.V108.11.5006.5006

Published: 2006

Journal Articles

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.

Evangelos Terpos, MD, PhD, Athanasios Anagnostopoulos, MD, PhD, Efstathios Kastritis, MD, Athanasios Zomas, MD, Christos Poziopoulos, MD, Nikolaos Anagnostopoulos, MD, PhD, Konstantinos Tsionos, MD, Meletios A. Dimopoulos, MD, PhD

Blood (2005) 106 (11): 363.

https://doi.org/10.1182/blood.V106.11.363.363

Published: 2005

Journal Articles

Macrophage Inflammatory Protein-1 alpha (MIP-1α) Is Increased in Patients with Waldenstrom’s Macroglobulinemia and Correlates with the Severity of Disease.

Evangelos Terpos, MD, PhD, Athanasios Anagnostopoulos, MD, PhD, Efstathios Kastritis, MD, Aristotelis Bamias, MD, PhD, Konstantinos Tsionos, MD, Meletios A. Dimopoulos, MD, PhD

Blood (2005) 106 (11): 2498.

https://doi.org/10.1182/blood.V106.11.2498.2498

Published: 2005

Journal Articles

Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenstrom’s Macroglobulinemia: Correlations with Clinical Data.

Athanasios Anagnostopoulos, MD, PhD, Evangelos Terpos, MD, PhD, Efstathios Kastritis, MD, Aristotelis Bamias, MD, PhD, Konstantinos Tsionos, MD, Meletios A. Dimopoulos, MD, PhD

Blood (2005) 106 (11): 2504.

https://doi.org/10.1182/blood.V106.11.2504.2504

Published: 2005

NARROW

Bone Loss and High Bone Turnover in Patients with Non-Hodgkin's Lymphoma Who Receive Frontline Chemotherapy: Final Results of a Multicenter Prospective Study

Determination of the Percentage of CML Patients that Achieve Continuous Complete Molecular Response Under Treatment with TKIs and Are Eligible for Participation in a TKI Discontinuation Study

Low Bone Mineral Density and High Bone Turnover In Patients with Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study

First-Line Chemotherapy Leads to High Bone Turnover and Reduced Bone Mass in Patients with Non-Hodgkin's Lymphoma (NHL).

The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.

The Ratio of Angiopoietin-1 to Angiopoietin-2 Is Reduced and Predicts Independently for Survival in Newly Diagnosed Patients with Multiple Myeloma.

Cystatin-C Is a Sensitive Marker of Renal Impairment with an Independent Predictive Value for Survival in Multiple Myeloma; Reduction Post Bortezomib Monotherapy.

Bone Remodeling in Patients with Relapsed/Refractory Multiple Myeloma Who Receive Lenalidomide-Based Regimens.

Dysfunction of Toll-Like Receptor-2, −4, and −6: Is There a Role in the Pathogenesis of Immunodeficiency in Multiple Myeloma?.

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1α and Angiogenic Cytokines.

Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenastrom’s Macroglobulinemia (WM): Correlations with Clinical Data.

The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Treatment for Relapsed/Refractory Myeloma: Results of a Phase II Clinical Trial.

Macrophage Inflammatory Protein-1 alpha (MIP-1α) Is Increased in Patients with Waldenstrom’s Macroglobulinemia and Correlates with the Severity of Disease.

Angiogenic Cytokines Are Increased in the Serum of Patients with Waldenstrom’s Macroglobulinemia: Correlations with Clinical Data.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only